Fast and lasting relief
- Frequently provides relief in 1 week2
- 34% reduction in mean total AUA Symptom Score at 4 Days vs. terazosin 1 mg3
- Urine flow improvement seen in as little as 4 Hours4
Trusted safety
- No clinically meaningful effect on blood pressure4,5,6
- Significantly lower incidence of symptomatic postural hypotension than with terazosin or doxazosin reported in meta-analyses from single-arm, randomized controlled trials7
Proven tolerability
- Discontinuation rates for the 5 most commonly reported adverse events for tamsulosin 0.4 mg comparable to placebo3
Easy to prescribe
Most widely accepted branded alpha-blocker
- Reimbursed by 98% of managed care organizations8
 |
Learn more about the proven efficacy of FLOMAX |
Important Safety Information
FLOMAX is indicated to treat the signs and symptoms of benign prostatic hyperplasia (BPH). FLOMAX is not indicated to treat hypertension. As with other alpha-adrenergic blocking agents, there is a potential risk of syncope. Patients beginning treatment with FLOMAX should be cautioned to avoid driving or hazardous tasks for 12 hours after their first dose or increase in dose should syncope occur. The most common side effects are dizziness, abnormal ejaculation, and rhinitis.
Caution should be exercised with concomitant administration of warfarin and FLOMAX. In addition, FLOMAX should be used with caution in combination with cimetidine, particularly at doses higher than 0.4 mg. FLOMAX is contraindicated in patients known to be hypersensitive to tamsulosin HCl or any component of FLOMAX.
Before prescribing FLOMAX, please see the full Prescribing Information.
1. IMS Health, National Disease and Therapeutic Index (NDTI™), IMS Health, National Prescription Audit (NPA), 2001 - December 2002 and IMS Health, Next Generation Prescription Services (NGPS), 2003 - May 2006, using customized BPH diagnosis and factored prescriptions.
2. FLOMAX Prescribing Information, Boehringer Ingelheim Pharmaceuticals, Inc.
3. Data on file, Boehringer Ingelheim Pharmaceuticals, Inc.
4. Lepor H, for the Tamsulosin Investigator Group. Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Urology. 1998;51:892-900.
5. Narayan P, Tewari A, and Members of United States 93-01 Study Group. A second phase III multicenter placebo-controlled study of 2 dosages of modified release tamsulosin in patients with symptoms of benign prostatic hyperplasia. J Urol. 1998;160:1701-1706.
6. Lowe FC. Coadministration of tamsulosin and three antihypertensive agents in patients with benign prostatic hyperplasia: pharmacodynamic effect. Clin Ther. 1997;19:730-742.
7. American Urological Association. Guideline on the Management of Benign Prostatic Hyperplasia (BPH). Linthicum, Md: American Urological Association Education and Research, Inc; 2003:1-22,1-23,3-51.
8. Verispan’s Managed Care Formulatory Drug Audit, Spring 2007.
